Bakács Tibor, Mehrishi J N
The Cambridge Chronic Hepatitis - AIDS New Treatment Strategy Development Initiative, Macfarlane Cl. 13, Impington, Cambridge CB4 9LZ, UK.
Vaccine. 2004 Nov 15;23(1):3-13. doi: 10.1016/j.vaccine.2004.08.005.
Hepatitis virus infection persistent worldwide (approximately 600 m people) results in chronic hepatitis progressing to hepatocellular carcinoma (HCC) in many (approximately 1 m deaths/year). The review examines the usefulness of treating chronic viral hepatitis, including decompensated patients, by intentional coinfection with an attenuated infectious bursal disease virus (IBDV; apathogenic in man, stable at pH 2, orally administered). Learning lessons from the IBDV studies, the case is made to treat human immunodeficiency virus (HIV) infected patients (worldwide prevalence approximately 50 m people) by coinfecting with apathogenic hepatitis G virus (GBV-C). These ideas are reinforced by (i) eight out of ten studies reporting a beneficial effect of GBV-C viremia on HIV-related mortality or response to therapy and (ii) the recent reports of improved or delayed survival of HIV patients, naturally coinfected with an apathogenic virus.
全球范围内持续性的肝炎病毒感染（约6亿人）会导致慢性肝炎，其中许多人（每年约100万人死亡）会发展为肝细胞癌（HCC）。这篇综述探讨了通过故意共感染减毒传染性法氏囊病病毒（IBDV；对人类无致病性，在pH 2时稳定，口服给药）来治疗慢性病毒性肝炎（包括失代偿患者）的有效性。从IBDV研究中吸取经验教训，提出了通过与无致病性的庚型肝炎病毒（GBV-C）共感染来治疗人类免疫缺陷病毒（HIV）感染患者（全球患病率约5000万人）的案例。这些观点得到以下两方面的支持：（i）十分之八的研究报告称GBV-C病毒血症对HIV相关死亡率或治疗反应有有益影响；（ii）最近有报告称，自然感染无致病性病毒的HIV患者生存率提高或生存时间延迟。
